Moody's Ratings (Moody's) assigned a Ba2 rating to Coty, Inc.'s ("Coty") new senior secured notes. All other ratings including the company's Ba2 Corporate Family Rating (CFR), Ba2-PD Probability of Default Rating (PDR), Ba2 senior secured revolver and notes ratings, B1 senior unsecured note ratings ...
NEW YORK--(BUSINESS WIRE)-- Regulatory News: Coty Inc. (NYSE: COTY) (Paris: COTY)(“Coty”), one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care, today announced that it, together with its wholly-owned subsidiaries, HFC Prestige Products, Inc. and HFC Prestige International U.S. LLC (the “Co-Issuers” and collectively with Coty, the “Issuers”), launched an offering of €500 million aggregate principal amount of senior secured notes (the “Notes”), subject to market and customary conditions. The interest rates and ...
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update Last patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced financial results for the first quarter ended March 31, 2024, and provided a cor...
PubMatic to Participate at Upcoming Investor Summit NO-HEADQUARTERS/REDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- PubMatic, Inc. (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today announced that members of its management team are scheduled to participate at an upcoming investor summit. Details for the event are as follows: Evercore ISI 3rd Annual Nothing But Net Internet Summit in New York on Wednesday May 29, 2024. About PubMatic PubMatic (Nasdaq: PUBM) is an independent technology company maximizing custome...
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for the Prader-Willi syndrome community REDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today launched a groundbreaking initiative in honor of Prader-Willi Syndrome (PWS) Awareness Day. The campaign aims to raise awareness...
MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month: The Citizens JMP Life Sciences Conference (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside cha...
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 and Recent Corporate Highlights Closed on approximately $158.7 million underwritten public offering of 3,450,000 shares of common stock at a public of...
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent cor...
Oxbridge Re Holdings Limited Reports First Quarter 2024 Results GRAND CAYMAN, Cayman Islands, May 09, 2024 (GLOBE NEWSWIRE) -- (), (the “Company”), which together with its subsidiaries is engaged in the business of tokenized Real-World Assets (“RWAs”), initially in the form of tokenized reinsurance securities and reinsurance solutions primarily to property and casualty insurers, today reported its results for the three months ended March 31, 2024. “We were pleased with our core operational performance in the first quarter of 2024 in our Web-3 and reinsurance tokenization business," co...
Perma-Fix Reports Financial Results and Provides Business Update for the First Quarter of 2024 ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the first quarter ended March 31, 2024. Mark Duff, President and CEO of the Company, commented, “As previously disclosed, our financial performance in the first quarter of 2024 was impacted by a few temporary headwinds. However, we have seen steady improvement heading into the second quarter and anticipate a ...
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTACTM Pipeline Programs in Huntington’s Disease (HD) and Myotonic Dystrophy Type-1 (DM1) to Development Candidates Cash and Securities of $270.7 Million Support Multi-Year Operating Runway and Advancement of Up to Four Programs to Clinica...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.